Roche (ROG) investor relations material

Strategic progress and pipeline evolution

• Achieved 6% sales growth and double-digit core operating profit growth, with margin expansion since last Pharma Day, and HY 2026 sales up 6% and COP up 10% compared to the previous year, driven by disciplined focus on high-value assets and operational efficiency.

• Advanced six new molecular entities into phase III, now targeting up to 20 NMEs for potential launch by 2030, with major late-stage readouts expected from 2027 to 2030 in IBD, Alzheimer's, MASH, Parkinson's, obesity, and hypertension.

• Discontinued lower-potential programs and added promising assets like Tam-Peli and VEGF x IL-6 DutaFab, while raising divarasib revenue expectations based on strong data.

• No patent cliff expected through 2030; on-market portfolio and pipeline expected to drive sustained growth beyond 2030, with multiple launches anticipated including giredestrant, fenebrutinib, divarasib, vamikibart, Enspryng, sefaxersen, and afimkibart.

• Focused on five therapeutic areas (oncology/hematology, neurology, immunology, CVRM, ophthalmology) covering 60% of global disease burden and 80% of pharma industry growth.

R&D excellence and AI integration

• Fully implemented the 'bar' framework, resulting in a curated pipeline with higher average peak sales and portfolio value up 72%–93% since 2023.

• Achieved over 80% phase III success rate in 2026, with cycle times from lead identification to launch reduced by ~19 months over three years and 47 assets added since 2024 through early R&D and partnerships.

• Strategic external innovation through acquisitions and partnerships, including deals with Alnylam, Carmot, Telavant, and others, expanding modality breadth and pipeline quality.

• AI and agentic systems now impact 40% of portfolio decisions, accelerating target discovery, molecule design, and clinical trial interpretation, with proprietary models and autonomous labs scaling across R&D.

• AI-driven manufacturing and digital twins (e.g., Holly Springs plant, Lab-in-the-Loop) are modernizing production, improving yield, and enabling rapid tech transfer and network scalability.

Commercial and operational excellence

• Commercial strategy segmented into entrench (maximizing leadership in key areas), expand (new launches and indications), and establish (entering new disease areas such as obesity and hypertension to disrupt standards of care).

• Key on-market growth drivers include Phesgo, Polivy, Columvi, Lunsumio, Hemlibra (with upcoming autoinjector), Ocrevus (with subcutaneous and OBI devices), and Vabysmo.

• Giredestrant poised for launch in adjuvant and metastatic breast cancer, supported by robust evidence generation, patient access programs, and a major awareness campaign.

• Fenebrutinib set to redefine MS treatment as the first high-efficacy oral therapy for both RMS and PPMS, with strong phase III data and regulatory filings.

• Devices and digital solutions integrated to enhance patient experience and support upcoming launches, with marketed and pipeline assets mapped across archetypes to drive commercial synergies and broaden access.